# Berberine for Weight Loss: The Randomized Trial and the Meta-Analyses

By Ruth Calder, Enforcement Editor (https://glpwatchdog.org/authors/ruth-calder) | Published: 2026-11-04

Canonical page: https://glpwatchdog.org/research/berberine-for-weight-loss

> Pooled trials credit berberine with 0.88 kg more weight loss than control, and earlier analyses ranged from no effect to 2 kg. A 2026 double-blind trial in 337 adults with obesity found no difference from placebo in weight, visceral fat or liver fat after six months.

## Key points

- Largest pooled estimate (2026, 23 articles): 0.88 kg more weight lost than control, with a 95% CI of 0.39 to 1.36 kg.
- Two 2020 analyses with similar search dates disagreed: one found 2.07 kg, the other 0.11 kg and not significant.
- 2026 double-blind trial, 337 adults, 1 g a day for 6 months: weight −1.8 kg vs −1.9 kg on placebo.
- That trial also found no significant change in visceral fat or liver fat, though LDL cholesterol fell 7.72 mg/dL.
- For scale, semaglutide 2.4 mg produced −14.9% vs −2.4% on placebo at 68 weeks in STEP 1.

Berberine produces little weight loss: 0.88 kg more than control on average across 23 trials in the largest pooled analysis.[1] The best single trial found less. In 2026, a double-blind study of 337 adults with obesity reported weight changes of −1.8 kg on 1 gram of berberine a day and −1.9 kg on placebo after six months, with no significant difference in visceral fat or liver fat either.[2]

> **About this article.** It covers the randomized trials and meta-analyses of berberine and body weight, not its six-year colon polyp trial or what else berberine has been tested for. Doses named here describe what the studies gave and are not recommendations. GLP Watchdog sells no supplement.

## Does berberine help you lose weight?

On average, slightly at most. NIH’s complementary health center reaches the same view, saying some studies suggest it might help but the evidence is not conclusive, since many trials had a high risk of bias and their results were inconsistent.[3] Most participants also had conditions such as diabetes or fatty liver, and few trials were done in North America.[3]

To put 0.88 kg in context, it is about 1% of body weight for someone at 91 kg, roughly the average starting weight in the 2026 trial’s berberine group.[1][2] Its confidence interval runs from 0.39 to 1.36 kg.[1]

## What did the 2026 randomized trial find?

The study, called BRAVO and published in *JAMA Network Open*, is a strong test because it was double-blind and measured fat directly by CT scan. It enrolled adults with obesity and fatty liver disease but no diabetes at 11 hospitals in China, and gave them berberine hydrochloride 0.5 grams twice daily or a matching placebo for six months, along with lifestyle advice in both groups.[2]

*BRAVO trial: berberine 1 g a day vs placebo at 6 months*

| Measure | Berberine | Placebo | Difference (95% CI) |
| --- | --- | --- | --- |
| Body weight[2] | −1.8 kg | −1.9 kg | 0.05 kg (−0.74 to 0.84) |
| Body mass index[2] | −0.6 | −0.7 | 0.02 (−0.26 to 0.29) |
| Waist circumference[2] | −2.7 cm | −2.8 cm | −0.07 cm (−1.26 to 1.12) |
| Visceral fat area, relative change[2] | −0.6% | −2.0% | 1.4% (97.5% CI −2.4 to 5.2), not significant |

Weight, BMI and waist were secondary measures, and the main question was visceral and liver fat. Neither changed more than on placebo.[2] The study did find larger falls in LDL cholesterol (−7.72 mg/dL), apolipoprotein B and a marker of inflammation, which is consistent with what berberine does best.[2] A post hoc look suggested people with higher inflammation at baseline responded more, an idea that needs its own trial before anyone relies on it.[2]

Two design choices are relevant. Everyone first took berberine during a 30-day run-in, and those who could not tolerate it were excluded, so the trial is favorable to berberine on tolerance.[2] Both groups also lost weight on lifestyle advice alone, which is the kind of change an uncontrolled before-and-after study would have credited to the capsule. The same problem appears in [a gymnema meta-analysis with no control group](https://glpwatchdog.org/research/gymnema-sylvestre-a-meta-analysis-without-a-control).

## Why do the meta-analyses disagree?

Pooled estimates have ranged from no effect to about 2 kg, sometimes using searches run within months of each other.[4][5]

*Meta-analyses of berberine and body weight*

| Analysis | Studies pooled | Weight vs control | BMI vs control |
| --- | --- | --- | --- |
| Elahi Vahed, 2026[1] | 23 articles | −0.88 kg (−1.36 to −0.39) | −0.48 kg/m² |
| Asbaghi, 2020[4] | 12 studies | −2.07 kg (−3.09 to −1.05) | −0.47 kg/m² |
| Xiong, 2020[6] | 10 studies | −0.11 kg (−0.99 to 0.76), not significant | −0.29 kg/m² |
| Amini, 2020 (berberine and barberry)[5] | 12 trials, 849 people | −0.11 kg, not significant | −0.16 kg/m², not significant |
| Liu, 2025 (metabolic syndrome)[7] | Placebo-controlled trials only | Not among main results | −0.435 kg/m²; waist −3.27 cm |

Part of the gap comes from what each team counted as eligible: Amini also included barberry, Liu kept only placebo-controlled trials, and the populations ranged widely. The 2026 authors asked for better reporting of purity, potency and gram amounts, and for fixes to common problems of blinding and randomization.[1][5][7] When a pooled estimate depends on which trials enter it and a large blinded trial finds nothing, the fair reading is that any true effect is small.

## Do other berberine trials show weight loss?

- **Antipsychotic weight gain.** In 113 people with schizophrenia spectrum disorders and metabolic syndrome, 600 mg a day limited weight by 1.08 kg more than placebo at 12 weeks.[8]
- **Obesity, no placebo.** In a Mexican study of 50 adults, 500 mg three times daily lowered weight from baseline over three months, but the comparison group took gymnema, not placebo.[9]
- **Type 2 diabetes.** A pilot trial saw waist size fall and BMI stay at 26.0 over 13 weeks while HbA1c improved.[10] A 2025 trial of berberine plus cinnamon found no difference from placebo in body measurements.[11]

These results fit the rest of the record. Where berberine does move a number, it tends to be cholesterol or blood sugar rather than the scale, and the falls in [cholesterol on GLP-1 drugs](https://glpwatchdog.org/research/glp1-and-cholesterol) make a useful point of comparison.

## Does berberine work better for some people?

Possibly, though the evidence is at the level of subgroups. BRAVO’s post hoc look favored people with higher inflammation.[2] A meta-analysis of glucose outcomes found potentially larger falls in women, people with diabetes and Asian participants, and warned the comparisons rest on few studies and need replication.[12] Exposure differs too: after one 1,000 mg dose, women had 2.8 times the blood exposure of men, a finding that has not been tied to weight.[13] None of this identifies a group for whom berberine has been shown to produce meaningful weight loss.

## How much berberine was used in weight studies?

NIH notes that in a 2022 review, effects on weight appeared mainly at more than 1 gram a day for more than 8 weeks.[3] BRAVO’s negative result came at exactly 1 gram a day for six months, chosen for tolerability.[2] Whether more would have changed the answer is untested in a trial of that size. These amounts describe trials, not advice, and [the timing of doses](https://glpwatchdog.org/research/best-time-to-take-berberine) is a separate question.

## How does berberine compare with Wegovy or Zepbound?

The gap is large. In STEP 1, people on semaglutide 2.4 mg lost 14.9% of their body weight at 68 weeks against 2.4% on placebo, a difference of about 12 percentage points.[14] Trial groups and lengths differ, so the comparison is rough, but those differences cannot account for a gap of this size. [Wegovy](https://glpwatchdog.org/drugs/wegovy) and [Zepbound](https://glpwatchdog.org/drugs/zepbound) are FDA-approved drugs with labels built on such trials, while berberine reaches shelves with no approval requirement.[15]

No published trial has tested the two together. A 2026 interaction review calls people adding berberine to semaglutide or tirzepatide a population nobody has studied, and lists more low blood sugar and stomach effects as theoretical concerns.[16] One registered trial is recruiting to compare a multi-ingredient supplement containing berberine with and without semaglutide; it measures blood sugar, not weight.[17] Its side effects are a separate subject, and [the review of GLP-1 supplements](https://glpwatchdog.org/research/glp1-supplements-do-they-work) compares berberine with lemon extract, saffron and probiotics.

## Frequently asked questions

### How much weight can you lose with berberine?

The largest pooled analysis found 0.88 kg more than control, with a 95% confidence interval of 0.39 to 1.36 kg. A 2026 double-blind trial found a 1.8 kg loss on berberine and 1.9 kg on placebo over six months, so berberine added nothing measurable.

### Does berberine reduce belly fat?

The best test says no. A 2026 double-blind trial measured visceral fat by CT scan in adults with obesity and fatty liver, and 1 gram a day for six months did not lower it more than placebo. Liver fat did not differ either.

### Is berberine as good as Ozempic for weight loss?

No. Semaglutide, the ingredient in Ozempic, produced a 14.9% weight loss against 2.4% on placebo at the 2.4 mg Wegovy dose in STEP 1 at 68 weeks. Berberine’s pooled effect is under 1 kg, and berberine is not a GLP-1 drug.

### How long does berberine take to work for weight loss?

There is no established time course. NIH says that in one review effects on weight appeared mostly beyond 8 weeks at more than 1 gram a day, yet a six-month trial at 1 gram a day found no difference from placebo.

### Can you take berberine with a GLP-1 for weight loss?

No published trial has tested the combination. A 2026 interaction review describes people adding berberine to semaglutide or tirzepatide as unstudied, with low blood sugar and stomach effects as theoretical concerns. Check with the prescriber or a pharmacist first.

## References

1. Elahi Vahed I, Shahir-Roudi E, Nojumi S, et al. The effect of berberine on obesity indices: a systematic review and meta-analysis. International journal of obesity (2005). 2026. PMID: 41310257. DOI: 10.1038/s41366-025-01943-x. https://pubmed.ncbi.nlm.nih.gov/41310257/
2. Lei L, Wang B, Zhao L, et al. Berberine and Adiposity in Diabetes-Free Individuals With Obesity and MASLD: A Randomized Clinical Trial. JAMA network open. 2026. PMID: 41543854. DOI: 10.1001/jamanetworkopen.2025.54152. https://pubmed.ncbi.nlm.nih.gov/41543854/
3. National Center for Complementary and Integrative Health Berberine and Weight Loss: What You Need To Know. National Institutes of Health. 2023. https://www.nccih.nih.gov/health/berberine-and-weight-loss-what-you-need-to-know
4. Asbaghi O, Ghanbari N, Shekari M, et al. The effect of berberine supplementation on obesity parameters, inflammation and liver function enzymes: A systematic review and meta-analysis of randomized controlled trials. Clinical nutrition ESPEN. 2020. PMID: 32690176. DOI: 10.1016/j.clnesp.2020.04.010. https://pubmed.ncbi.nlm.nih.gov/32690176/
5. Amini MR, Sheikhhossein F, Naghshi S, et al. Effects of berberine and barberry on anthropometric measures: A systematic review and meta-analysis of randomized controlled trials. Complementary therapies in medicine. 2020. PMID: 32147051. DOI: 10.1016/j.ctim.2020.102337. https://pubmed.ncbi.nlm.nih.gov/32147051/
6. Xiong P, Niu L, Talaei S, et al. The effect of berberine supplementation on obesity indices: A dose- response meta-analysis and systematic review of randomized controlled trials. Complementary therapies in clinical practice. 2020. PMID: 32379652. DOI: 10.1016/j.ctcp.2020.101113. https://pubmed.ncbi.nlm.nih.gov/32379652/
7. Liu D, Zhao H, Zhang Y, et al. Efficacy and safety of berberine on the components of metabolic syndrome: a systematic review and meta-analysis of randomized placebo-controlled trials. Frontiers in pharmacology. 2025. PMID: 40740996. DOI: 10.3389/fphar.2025.1572197. https://pubmed.ncbi.nlm.nih.gov/40740996/
8. Chan M, Qin Z, Man SC, et al. Adjunctive berberine reduces antipsychotic-associated weight gain and metabolic syndrome in patients with schizophrenia: a randomized controlled trial. Psychiatry and clinical neurosciences. 2022. PMID: 34931749. DOI: 10.1111/pcn.13323. https://pubmed.ncbi.nlm.nih.gov/34931749/
9. Bandala C, Carro-Rodríguez J, Cárdenas-Rodríguez N, et al. Comparative Effects of Gymnema sylvestre and Berberine on Adipokines, Body Composition, and Metabolic Parameters in Obese Patients: A Randomized Study. Nutrients. 2024. PMID: 39064727. DOI: 10.3390/nu16142284. https://pubmed.ncbi.nlm.nih.gov/39064727/
10. Yin J, Xing H, Ye J Efficacy of berberine in patients with type 2 diabetes mellitus. Metabolism: clinical and experimental. 2008. PMID: 18442638. DOI: 10.1016/j.metabol.2008.01.013. https://pubmed.ncbi.nlm.nih.gov/18442638/
11. Mansour A, Sajjadi-Jazi SM, Gerami H, et al. The efficacy and safety of berberine in combination with cinnamon supplementation in patients with type 2 diabetes: a randomized clinical trial. European journal of nutrition. 2025. PMID: 39998703. DOI: 10.1007/s00394-025-03618-9. https://pubmed.ncbi.nlm.nih.gov/39998703/
12. Zhao JV, Huang X, Zhang J, et al. Overall and Sex-Specific Effect of Berberine on Glycemic and Insulin-Related Traits: a Systematic Review and Meta-Analysis of Randomized Controlled Trials. The Journal of nutrition. 2023. PMID: 37598753. DOI: 10.1016/j.tjnut.2023.08.016. https://pubmed.ncbi.nlm.nih.gov/37598753/
13. Blöcher JA, Meyer-Tönnies MJ, Morof F, et al. Sex-Dependent Effects of CYP2D6 on the Pharmacokinetics of Berberine in Humans. Clinical pharmacology and therapeutics. 2025. PMID: 39488825. DOI: 10.1002/cpt.3454. https://pubmed.ncbi.nlm.nih.gov/39488825/
14. Wilding JPH, Batterham RL, Calanna S, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity. The New England journal of medicine. 2021. PMID: 33567185. DOI: 10.1056/NEJMoa2032183. https://pubmed.ncbi.nlm.nih.gov/33567185/
15. US Food and Drug Administration Questions and Answers on Dietary Supplements. FDA. 2026. https://www.fda.gov/food/information-consumers-using-dietary-supplements/questions-and-answers-dietary-supplements
16. Dumitru CN, Marcu T, Dumitru AO, et al. Berberine-Drug Interactions: Mechanisms, Clinical Relevance and Risk Stratification-A Narrative Review. Pharmaceuticals (Basel, Switzerland). 2026. PMID: 42653808. DOI: 10.3390/ph19081313. https://pubmed.ncbi.nlm.nih.gov/42653808/
17. ClinicalTrials.gov A Clinical Trial to Examine the Efficacy and Safety of an Investigational Product With and Without Use of Semaglutide on Glycemic Response in Adults With Prediabetes or Type 2 Diabetes (NCT07195994). U.S. National Library of Medicine. 2025. https://clinicaltrials.gov/study/NCT07195994

---

Cite as: GLP Watchdog, Ruth Calder, "Berberine for Weight Loss: The Randomized Trial and the Meta-Analyses", published 2026-11-04. https://glpwatchdog.org/research/berberine-for-weight-loss

Canonical HTML page: https://glpwatchdog.org/research/berberine-for-weight-loss

Medical disclaimer: Nothing here is medical advice. We report on this subject; we do not treat anyone. Whether to begin a medication, supplement, or treatment, whether to adjust it, and whether to stop are questions for a clinician licensed to answer them, who knows your history.